MECCA - A DEVELOPMENTAL, DOSE-INTENSIVE, NON-CROSS-RESISTANT PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER

Citation
Pj. Hoskins et al., MECCA - A DEVELOPMENTAL, DOSE-INTENSIVE, NON-CROSS-RESISTANT PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER, Gynecologic oncology, 63(3), 1996, pp. 345-351
Citations number
28
Categorie Soggetti
Oncology,"Obsetric & Gynecology
Journal title
ISSN journal
00908258
Volume
63
Issue
3
Year of publication
1996
Pages
345 - 351
Database
ISI
SICI code
0090-8258(1996)63:3<345:M-ADDN>2.0.ZU;2-H
Abstract
Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma w ere treated with a developmental combination chemotherapy regimen cons isting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA). This protocol utilized the concepts of dose intensity, front-end loadi ng, non-cross-resistance, and synergy. The median overall survival was 37 months with a 27% 5-year survival; the median failure-free surviva l was 15 months with a 14% 5-year failure-free rate. The predominant t oxicity was hematologic and there was one toxic death (cardiac failure ). The overall survival results are superior to our previous experienc e. (C) 1996 Academic Press, Inc.